Microarrays in drug development: regulatory perspective

  • Roland Frötschl
  • Peter Kasper
Part of the Progress in Inflammation Research book series (PIR)


This chapter describes the current status and impact of data from microarray applications on drug development and approval from a European regulator’s point of view.

Microarray technology is regarded as a new, valuable and increasingly important tool in drug development and risk evaluation. The technique may enable faster development of new and safer drugs, even for diseases as yet incurable. Scientists in industry, academia, and regulatory bodies are currently evaluating and discussing what prerequisites are needed to implement microarray data from pharmacogenetic, pharmcogenomic, and toxicogenomic experiments in the regulatory process and for use in risk/benefit evaluations.

The areas where microarray applications are considered meaningful are identified and the activities and expectations of regulatory bodies discussed. The proposed measures of quality control and assurance are presented as outlined in the draft guidance paper by FDA and a draft reflection paper by EMEA. The current discussion on how to define and qualify biomarkers for prediction of pharmacologic/toxicologic effects, and their implementation in the regulatory framework and decision making is described.

In an overview, regulatory experience with microarray data submissions so far is presented. Our general expectation is that requests for pharmacogenetic briefing meetings and voluntary genomics data submission will increase substantially in the near future, also leading the way to increasing data submissions with marketing applications.


Microarray Data Drug Development Regulatory Body Risk Evaluation Regulatory Framework 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Afshari CA, Nuwaysir EF, Barrett JC (1999) Application of complementary DNA microarray technology to carcinogen identification, toxicology and drug safety evaluation. Cancer Res 59: 4759–4760PubMedGoogle Scholar
  2. 2.
    Lovett RA (2000) Toxicologists brace for genomics revolution. Science 289: 536–537PubMedCrossRefGoogle Scholar
  3. 3.
    Pollack A (2000) DNA chip may help usher in a new area of product testing. New York Times 28 Nov 2000Google Scholar
  4. 4.
    Lühe A, Suter L, Ruepp S, Singer T, Weiser T, Albertini S (2005) Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit? Mutat Res 575: 102–115PubMedGoogle Scholar
  5. 5.
    Heidecker B, Hare JM (2007) The use of transcriptomic biomarkers for personalized medicine. Heart Fail Rev 12: 1–11PubMedCrossRefGoogle Scholar
  6. 6.
    Fischer HP, Freiberg C (2007) Applications of transcriptional profiling in antibiotics discovery and development. Prog Drug Res 64: 21, 23–47PubMedCrossRefGoogle Scholar
  7. 7.
    Lesko LJ, Woodcock J (2002) Pharmacogenomic-guided drug development: a regulatory perspective. Pharmacogenomics J 2: 20–24PubMedCrossRefGoogle Scholar
  8. 8.
    FDA (2004) Challenge and opportunity on the critical path to new medical products (http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf)Google Scholar
  9. 9.
    FDA (2005) Guidance for Industry: Pharmacogenomic Data Submissions (http://www. fda.gov/cder/guidance/6400fnl.pdf)Google Scholar
  10. 10.
    FDA(2007) Guidance for industry and FDA staff: Pharmacogenetic tests and genetic tests for heritable markers(http://www.fda.gov/cdrh/oivd/guidance/1549.pdf)Google Scholar
  11. 11.
    EMEA (2006) Guideline on Pharmacogenetics Briefing Meetings (http://www.emea. europa.eu/pdfs/human/pharmacogenetics/2022704en.pdf)Google Scholar
  12. 12.
    FDA, EU, EMEA (2006) General principles: Processing Joint FDA EMEA Voluntary Genomic Data Submissions (VGDSs) within the framework of the Confidentiality Arrangement (http://www.emea.europa.eu/pdfs/human/pharmacogenetics/Guideline_on_Joint_VGDS_briefingmeetings.pdf)Google Scholar
  13. 13.
    ICH (2007) Final Draft Guideline E15: Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding catagories (http://www.ich.org/LOB/media/MEDIA3383.pdf)Google Scholar
  14. 14.
    Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates. Nat Rev Drug Discov 3:711–715PubMedCrossRefGoogle Scholar
  15. 15.
    FDA(2006) Table of valid genomic biomarkers in the context of approved drug labels (http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm) last updated Oct 27, 2006Google Scholar
  16. 16.
    Waters M, Yauk C (2007) Consensus recommendations to promote and advance predictive systems toxicology and toxicogenomics. Environ Mol Mutagen 48: 400–403PubMedCrossRefGoogle Scholar
  17. 17.
    Lipshutz RJ, Morris D, Chee M, Hubbell E, Kozal MJ, Shah N, Shen N, Yang R, Fodor SP(1995) Using oligonucleotide probe arrays to access genetic diversity. Biotechniques 19: 442–447PubMedGoogle Scholar
  18. 18.
    Ramsay G (1998) DNA chips: state-of-the-art. Nat Biotechnol 16: 40–44PubMedCrossRefGoogle Scholar
  19. 19.
    Frueh FW (2006) Impact of microarray data quality on genomic data submissions to the FDA. Nat Biotechnol 24: 1105–1107PubMedCrossRefGoogle Scholar
  20. 20.
    Chan VSW, Theilade MD (2005) The use of toxicogenomic data in risk assessment: a regulatory perspective. Clin Toxicology 43: 121–126Google Scholar
  21. 21.
    Gruvberger-Saal SK, Cunliffe HE, Carr KM, Hedenfalk IA (2006) Microarrays in breast cancer research and clinical practice — the future lies ahead. Endocr Rel Cancer 13: 1017–1031CrossRefGoogle Scholar
  22. 22.
    Surowiak P (2006) Prediction of the response to chemotherapy in ovarian cancers. Folia Morphol 65: 285–294Google Scholar
  23. 23.
    Achiron A, Gurevich M, Snir Y, Segal E, Mandel M (2007) Zinc-ion binding and cytokine activity regulation pathway predicts outcome in relapsing-remitting multiple sclerosis. Clin Exp Immunol 149: 235–242PubMedCrossRefGoogle Scholar
  24. 24.
    Dietel M (2007) Predictive pathology of cytostatic drug resistance and new anti-cancer targets. Recent Results Cancer Res 176: 25–32PubMedCrossRefGoogle Scholar
  25. 25.
    Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC et al (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29: 365–371PubMedCrossRefGoogle Scholar
  26. 26.
    The Microarray Quality Control Consortium (2006) Nat Biotechnol 24: 1103–1169CrossRefGoogle Scholar
  27. 27.
    Pozhitkov AE, Tautz D, Noble PA (2007) Oligonucleotide microarrays: widely applied poorly understood. Brief Funct Genomic Proteomic 6: 141–148PubMedCrossRefGoogle Scholar
  28. 28.
    FDA (2007) Draft Guidance for Industry — Pharmacogenomic data submissions — companion guidance (http://www.fda.gov/cder/guidance/7735dft.pdf)Google Scholar
  29. 29.
    EMEA (2007) Reflection paper on pharmacogenomic samples, testing and data handling (http://www.emea.europa.eu/pdfs/human/pharmacogenetics/20191406en.pdf)Google Scholar
  30. 30.
    Pennie W, Pettit, SD, Lord PG (2004) Toxicogenomics in risk assessment: An overview of an ILSI HESI collaborative research program. Environ Health Perspect 112: 417–419PubMedGoogle Scholar
  31. 31.
    Foster WR, Chen SJ, He A, Truong A, Bhaskaran V, Nelson DM, Dambach DM, Lehman-McKeeman LD, Car BD (2007) A retrospective analysis of Toxicogenomics in the safety assessment of drug candicates. Toxicol Pathol 35: 621–635PubMedCrossRefGoogle Scholar
  32. 32.
    Goodsaid F, Frueh F (2006) Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 7: 773–782PubMedCrossRefGoogle Scholar
  33. 33.
    Goodsaid F, Frueh F (2007) Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J 9: E105–E108.PubMedCrossRefGoogle Scholar
  34. 34.
    EMEA (2008) First EMEA-FDA joint biomarker qualification process (http://www.emea.europa.eu/htms/human/mes/biomarkers.htm)Google Scholar
  35. 35.
    Orr MS, Goodsaid F, Amur S, Rudman A, Frueh FW (2007) The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program. Clin Pharmacol Ther 81: 294–297PubMedCrossRefGoogle Scholar
  36. 36.
    Kasper P, Oliver G, Lima BS, Singer T, Tweats D (2005) Joint EFPIA/CHMP SWP Workshop: the Emerging Use of Omic Technologies for Regulatory Non-Clinical Safety Testing. Pharmacogenomics 6: 181–184PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2008

Authors and Affiliations

  • Roland Frötschl
    • 1
  • Peter Kasper
  1. 1.Federal Institute for Drugs and Medical Devices (BfArM)BonnGermany

Personalised recommendations